

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UPDATED INFORMATION OF THE GROUP'S PRODUCTS

This announcement is made by The United Laboratories International Holdings Limited (the “Company”) on a voluntary basis.

The board of directors (the “Board”) of the Company is pleased to announce that on 25 May 2021, Zhuhai United Laboratories Co., Ltd. (珠海聯邦制藥股份有限公司), a wholly-owned subsidiary of the Company, received a notice of clinical trial approval issued by the National Medical Products Administration regarding insulin aspart 50 injection applied by the Company with approval number of CXSL1900081.

Insulin aspart 50 injection is a premixed insulin analogue consisting of 50% soluble insulin aspart and 50% protamine insulin aspart. Compared with soluble human insulin, insulin aspart 50 is characterized by both rapid onset of action and basic blood glucose control. In addition, Insulin aspart 50 has advantages in improving blood glucose control and drug compliance.

The Company will continue to be devoted to the research and development of new products and enhance its competitiveness and innovation in the biopharmaceutical industry, which is expected to create more values for the Company and its shareholders.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 31 May 2021

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.